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ABSTRACT 
 
 
Background: Cystic fibrosis (CF) is the most common life-shortening autosomal recessive disease in 
Caucasians. It is a multi-organ disease that results from mutations in the gene that encodes the CF 
transmembrane conductance regulator (CFTR) protein, which regulates ion transport at epithelial 
surfaces. The main clinical characteristics are progressive pulmonary disease and pancreatic 
insufficiency. Not long ago most affected patients died in childhood. The outlook for patients with CF 
has improved steadily over the years, as a result of more aggressive therapy and care in specialised 
centres. Current understanding of the molecular-biological defect that underlies CF will lead to new 
treatments. To benefit from these new treatments, patients should have as few irreversible lesions as 
possible. An early CF diagnosis by newborn screening is therefore highly desired. The overall aim of 
this thesis was to provide a basis for discussion of whether CF should be included in the national 
newborn screening programme in Sweden. 
Paper I is a multi-centre study in which we analysed the CFTR mutation in 75% of the Swedish CF 
population (331 patients). The three most common CFTR mutations were deltaF508 68.3%, 394delTT 
8.5% and 3659delC 7.9%, comprising 84.6% of the CF alleles in the material. This result shows that 
newborn screening for CF with an IRT/DNA approach is possible in Sweden. 
Paper II is a questionnaire study of parental attitudes towards newborn screening for CF in which the 
parents of 143 CF patients and parents of children in two age-matched control groups participated. A 
majority of the parents, 70-86% in the different groups of parents, supported screening for CF. The 
parental attitude of CF parents was independent of the age of the child, the delay of diagnosis as 
experienced by the parents, and the well-being of the CF child at the time of diagnosis. 
Paper III is a questionnaire study to the parents of the same 143 CF patients as in Paper II to 
investigate their experiences after the clinical CF diagnosis of their child, and to find out the effects of 
the diagnosis on the family. The parental experiences on receiving a clinical CF diagnosis were intense 
and emotional. The parents stated that the CF diagnosis greatly influenced other family members, such 
as siblings and grandparents. A majority of the CF families had not experienced any change in 
relationships within the family, or in the social life of the family, one year after the diagnosis. 
Paper IV is a register study of 119 CF patients born between 1974 and 2001 in which we studied 
disease progression over time for lung, liver, nutritional and overall morbidity with Kaplan-Meier 
curves and proportional hazards regressions. The median age at diagnosis of the patients was 5 
months. The patients with overall morbidity at diagnosis showed a slow decline of symptoms, with 
half of the patients becoming free of overall morbidity after 4.8 years; however, the patients who were 
older than 24 months at diagnosis had a lower probability of becoming free of morbidity (crude 
hazards ratio 0.14 [95% confidence interval 0.04, 0.45]) than those with an earlier diagnosis, at the age 
of 2-12 months (p < 0.01).  
Paper V is a register study of all patients in the Stockholm CF Centre register with the diagnosis of CF 
and two verified CFTR mutations, in total 220 patients. CFTR mutations or larger deletions were found 
in all patients with classic CF. There was no statistical difference in lung function using the mixed 
model analysis for the different mutation groups studied. Patients born after 1985 had better lung 
function (FEV1 and FVC) than those born earlier.  
Conclusion: Our studies show that the conditions for a newborn screening programme for CF in 
Sweden are good and that a majority of parents in Sweden support the inclusion of CF in the newborn 
screening programme. 
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